Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib

Gilberto De Lima Lopes, Caio Max Rocha Lima

Research output: Contribution to journalArticlepeer-review


A 50-year-old man had a metastatic gastrointestinal stromal tumor that was refractory to imatinib. He was prescribed a 6-week course of treatment with oral sunitinib 50 mg/day. During the fourth week of his first cycle of treatment with the drug, the patient developed acute-onset, right upper quadrant pain associated with nausea, vomiting, and fever; laboratory tests revealed leukocytosis and mild hyperbilirubinemia. He was diagnosed with acute emphysematous cholecystitis, which was treated with broad-spectrum antibiotics and percutaneous cholecystostomy. His symptoms resolved, and he successfully completed his course of therapy with sunitinib. Using the Naranjo adverse drug reaction probability scale, a score of 5 was derived, which indicates that the likelihood was probable that this adverse event was caused by sunitinib.

Original languageEnglish (US)
Pages (from-to)775-777
Number of pages3
Issue number5
StatePublished - May 1 2007


  • Angiogenesis
  • Emphysematous cholecystitis
  • Gastrointestinal stromal tumor
  • Sunitinib
  • VEGF
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib'. Together they form a unique fingerprint.

Cite this